Eagle-eyed Warning: Kunming Pharmaceuticals' Operating Revenue Declined

Sina Finance Listed Company Research Institute | Financial Report Eagle Eye Warning

On March 19, Kunming Pharmaceutical Group released its 2025 annual report.

The report shows that the company’s total operating revenue for 2025 was 6.575 billion yuan, a decrease of 21.74% year-over-year; net profit attributable to shareholders was 350 million yuan, down 46%; net profit excluding non-recurring gains and losses was 107 million yuan, down 74.45%; basic earnings per share were 0.46 yuan.

Since listing in December 2000, the company has paid cash dividends 20 times, totaling 1.928 billion yuan.

The listed company financial report Eagle Eye warning system performs intelligent quantitative analysis of Kunming Pharmaceutical Group’s 2025 annual report from four dimensions: performance quality, profitability, funding pressure and safety, and operational efficiency.

1. Performance Quality

During the reporting period, the company’s revenue was 6.575 billion yuan, down 21.74% YoY; net profit was 419 million yuan, down 44.22%; net cash flow from operating activities was 289 million yuan, down 64.21%.

Overall performance analysis highlights:

• Revenue decline. During the reporting period, revenue was 6.58 billion yuan, a 21.74% decrease.

• Significant drop in net profit attributable to shareholders. During the reporting period, net profit was 350 million yuan, a 46% decrease.

• Continuous decline in net profit excluding non-recurring gains and losses. Over the last three annual reports, YoY change in non-recurring net profit was 33.45%, 25.09%, and -74.45%, with a persistent downward trend.

• Profitability fluctuates significantly. Over the last three annual reports, net profits were 450 million yuan, 750 million yuan, and 419 million yuan, with YoY changes of 17.82%, 16.89%, and -44.22%, respectively.

Operational asset quality analysis:

• Accounts receivable/revenue ratio continues to grow. Over the last three annual reports, ratios are 33.12%, 33.53%, and 51.17%, showing a steady increase.

Cash flow quality analysis:

• Operating cash flow/net profit ratio below 1. During the reporting period, the ratio was 0.69, indicating weaker profitability quality.

2. Profitability

During the reporting period, the company’s gross profit margin was 38.52%, down 11.36% YoY; net profit margin was 6.37%, down 28.72%; return on equity (weighted) was 6.58%, down 30.88%.

Key profitability concerns:

• Continuous decline in gross profit margin. Over the last three annual reports, gross margins were 44.82%, 43.46%, and 38.52%, showing a downward trend.

• Sharp decrease in net profit margin. During the reporting period, net profit margin was 6.37%, a significant drop of 28.72%.

Asset-side profitability analysis:

• Return on equity (ROE) significantly declined. During the period, weighted average ROE was 6.58%, down 30.88% YoY.

Unusual gains and losses:

• High proportion of non-recurring gains. During the period, non-recurring gains/Net profit ratio was 47.1%. (Note: Non-recurring gains include investment income, fair value changes, non-operating income, and losses on disposal of non-current assets).

3. Funding Pressure and Safety

During the reporting period, the company’s asset-liability ratio was 41.04%, down 11.75% YoY; current ratio was 2.02; quick ratio was 1.66; total debt was 1.89 billion yuan, with short-term debt at 1.206 billion yuan, accounting for 63.84% of total debt.

Funding management focus:

• Interest income / monetary funds ratio below 1.5%. During the period, monetary funds were 1.23 billion yuan, short-term debt was 950 million yuan, with an average interest income/monetary funds ratio of 0.571%, below 1.5%.

4. Operating Efficiency

During the period, accounts receivable turnover was 2.13 times, down 29.25%; inventory turnover was 2.77 times, down 3.57%; total asset turnover was 0.54 times, down 20.06%.

Asset management focus:

• Accounts receivable turnover rate continues to decline. Over the last three annual reports, ratios are 3.09, 3.01, and 2.13, indicating weakening collection efficiency.

Long-term asset management:

• Total asset turnover rate continues to decline. Over the last three reports, ratios are 0.81, 0.67, and 0.54, showing decreasing efficiency.

• Construction in progress fluctuates significantly. During the period, in-progress projects amounted to 100 million yuan, a 31.31% increase from the beginning of the period.

• Other non-current assets fluctuate notably. During the period, other non-current assets were 40.51 million yuan, a 33.63% increase from the beginning.

Click on Kunming Pharmaceutical Group Eagle Eye Warning to view the latest alerts and visualized financial report preview.

Sina Finance Listed Company Financial Report Eagle Eye Warning Introduction: The Eagle Eye Warning system is an intelligent professional analysis platform for listed company financial reports. It gathers authoritative financial experts from accounting firms and listed companies to track and interpret the latest financial reports from multiple dimensions such as performance growth, earnings quality, funding pressure and safety, and operational efficiency, providing visual alerts of potential financial risks. It offers professional, efficient, and convenient technical solutions for financial institutions, listed companies, and regulatory authorities to identify and warn of financial risks.

Eagle Eye Warning Access: Sina Finance APP - Market - Data Center - Eagle Eye Warning or Sina Finance APP - Stock Quote Page - Financial - Eagle Eye Warning

Disclaimer: The market involves risks; investment should be cautious. This article is automatically published based on third-party databases and does not represent Sina Finance’s views. All information herein is for reference only and does not constitute personal investment advice. Please refer to official announcements for accuracy. For questions, contact biz@staff.sina.com.cn.